JCR Pharmaceuticals Wins Conditional Approval for IZCARGO in Kuwait
JCR Pharmaceuticals received conditional marketing authorization in Kuwait for Izcargo, its blood-brain barrier-penetrating enzyme replacement therapy for Hunter syndrome. Kuwait is the second market outside Japan to authorize the treatment, following the United Arab Emirates in July 2026. Disclaimer: This news brief w